EyePoint Pharmaceuticals (NSDQ:EYPT) said today that it received $28.9 million in proceeds from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors and another accredited investor. Last month, the Watertown, Mass.-based company won transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu, from the Centers for Medicare and Medicaid Services. The FDA-approved product […]
eyepointpharmaceuticals
EyePoint nabs CMS reimbursement for Dexycu cataract surgery drug
EyePoint Pharmaceuticals (NSDQ:EYPT) said this week that the Centers for Medicare and Medicaid Services approved transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu. The FDA-approved product is designed to treat inflammation following cataract surgery using a single, intraocular dose of long-acting dexamethasone. “The receipt of pass-through status and the assignment of a […]
